Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840–51.

Article  CAS  PubMed  Google Scholar 

Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost. 2013;39:559–66.

Article  CAS  PubMed  Google Scholar 

Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131:417–30.

Article  CAS  PubMed  Google Scholar 

Ogura H, Gando S, Saitoh D, Takeyama N, Kushimoto S, Fujishima S, Mayumi T, Araki T, Ikeda H, Kotani J, et al. Epidemiology of severe sepsis in Japanese intensive care units: a prospective multicenter study. J Infect Chemother. 2014;20:157–62.

Article  PubMed  Google Scholar 

Gando S. Role of fibrinolysis in sepsis. Semin Thromb Hemost. 2013;39:392–9.

Article  CAS  PubMed  Google Scholar 

Matsuoka T, Yamakawa K, Iba T, Homma K, Sasaki J. Persistent and late-onset disseminated intravascular coagulation are closely related to poor prognosis in patients with Sepsis. Thromb Haemost; 2023.

Iba T, Umemura Y, Watanabe E, Wada T, Hayashida K, Kushimoto S. Japanese surviving Sepsis Campaign Guideline Working Group for disseminated intravascular c: diagnosis of sepsis-induced disseminated intravascular coagulation and coagulopathy. Acute Med Surg. 2019;6:223–32.

Article  PubMed  PubMed Central  Google Scholar 

Lyons PG, Micek ST, Hampton N, Kollef MH. Sepsis-Associated Coagulopathy Severity predicts Hospital Mortality. Crit Care Med. 2018;46:736–42.

Article  PubMed  Google Scholar 

Kobayashi N, Maekawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol 1983:265–75.

Taylor FB Jr., Toh CH, Hoots WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation of the International Society on T, Haemostasis: towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–30.

Article  CAS  PubMed  Google Scholar 

Gando S, Wada H, Asakura H, Iba T, Eguchi Y, Okamoto K, Ohtomo Y, Kawasugi K, Koga S, Koseki K, et al. Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clin Appl Thromb Hemost. 2005;11:71–6.

Article  PubMed  Google Scholar 

Tanaka K, Takeba J, Matsumoto H, Ohshita M, Annen S, Moriyama N, Nakabayashi Y, Aibiki M. Anticoagulation therapy using rh-thrombomodulin and/or Antithrombin III Agent is Associated with reduction in in-hospital mortality in septic disseminated intravascular coagulation: a Nationwide Registry Study. Shock. 2019;51:713–7.

Article  CAS  PubMed  Google Scholar 

Yamakawa K, Umemura Y, Murao S, Hayakawa M, Fujimi S. Optimal timing and early intervention with anticoagulant therapy for Sepsis-Induced disseminated Intravascular Coagulation. Clin Appl Thromb Hemost. 2019;25:1076029619835055.

Article  PubMed  PubMed Central  Google Scholar 

Hayakawa M, Kudo D, Saito S, Uchino S, Yamakawa K, Iizuka Y, Sanui M, Takimoto K, Mayumi T, Ono K, et al. Antithrombin Supplementation and Mortality in Sepsis-Induced disseminated intravascular coagulation: a Multicenter Retrospective Observational Study. Shock. 2016;46:623–31.

Article  CAS  PubMed  Google Scholar 

Yamakawa K, Gando S, Ogura H, Umemura Y, Kabata D, Shintani A, Shiraishi A, Saitoh D, Fujishima S, Mayumi T, et al. Identifying Sepsis populations benefitting from anticoagulant therapy: a prospective cohort study incorporating a restricted cubic spline regression model. Thromb Haemost. 2019;119:1740–51.

Article  PubMed  Google Scholar 

Vincent JL, Francois B, Zabolotskikh I, Daga MK, Lascarrou JB, Kirov MY, Pettila V, Wittebole X, Meziani F, Mercier E, et al. Effect of a recombinant human soluble thrombomodulin on mortality in patients with Sepsis-Associated Coagulopathy: the SCARLET Randomized Clinical Trial. JAMA. 2019;321:1993–2002.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869–78.

Article  CAS  PubMed  Google Scholar 

Gando S, Saitoh D, Ishikura H, Ueyama M, Otomo Y, Oda S, Kushimoto S, Tanjoh K, Mayumi T, Ikeda T, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care. 2013;17:R297.

Article  PubMed  PubMed Central  Google Scholar 

Mori S, Ai T, Sera T, Ochiai K, Otomo Y. Human soluble recombinant thrombomodulin, ART-123, resolved early phase coagulopathies, but did not significantly alter the 28 day outcome in the treatment of DIC Associated with Infectious systemic inflammatory response syndromes. J Clin Med 2019, 8.

Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238–47.

Article  CAS  PubMed  Google Scholar 

Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, Postier R, Hempelmann G, Butler T, Martin E, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med. 2001;29:2081–9.

Article  CAS  PubMed  Google Scholar 

Aoki N, Matsuda T, Saito H, Takatsuki K, Okajima K, Takahashi H, Takamatsu J, Asakura H, Ogawa N. Group C-ICR: a comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. Int J Hematol. 2002;75:540–7.

Article  CAS  PubMed  Google Scholar 

Baudo F, Caimi TM, de Cataldo F, Ravizza A, Arlati S, Casella G, Carugo D, Palareti G, Legnani C, Ridolfi L, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med. 1998;24:336–42.

Article  CAS  PubMed  Google Scholar 

Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson B, Brandt JT, Sundin DP, Levi M. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004;2:1924–33.

Article  CAS  PubMed  Google Scholar 

Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, Fourrier F, Heinrichs H, Delvos U. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. 1998;24:663–72.

Article  CAS  PubMed  Google Scholar 

Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest. 1993;104:882–8.

Article  CAS  PubMed  Google Scholar 

Hagiwara A, Tanaka N, Uemura T, Matsuda W, Kimura A. Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial. BMJ Open. 2016;6:e012850.

Article  PubMed  PubMed Central  Google Scholar 

Hsu JT, Chen HM, Chiu DF, Chen JC, Huang CJ, Hwang TL, Jan YY, Chen MF. Efficacy of gabexate mesilate on disseminated intravascular coagulation as a complication of infection developing after abdominal surgery. J Formos Med Assoc. 2004;103:678–84.

CAS  PubMed  Google Scholar 

Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M. Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock. 1997;8:328–34.

Article  CAS  PubMed  Google Scholar 

Jaimes F, De La Rosa G, Morales C, Fortich F, Arango C, Aguirre D, Munoz A. Unfractioned heparin for treatment of sepsis: a randomized clinical trial (the HETRASE Study). Crit Care Med. 2009;37:1185–96.

Article  CAS  PubMed  Google Scholar 

Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke HO, Warren BL, Opal SM. KyberSept I: treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006;4:90–7.

Article  CAS  PubMed  Google Scholar 

Nishiyama T, Kohno Y, Koishi K. Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study. Am J Emerg Med. 2012;30:1219–23.